Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug-drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug-drug interactions, would be easier to implement in practice.
Keywords: diabetic foot osteomyelitis; drug-drug interactions; rifamycins.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.